A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Urothelial Tract Cancer

Future Directions and Targeted Therapies in Bladder Cancer

“…Furthermore, investigation of pembrolizumab, an MAb targeting PD-1, is planned as a phase III trial in the salvage context following promising results in a phase Ib trial ( Table 1). 20 In this phase Ib trial, responses were seen in 24% of 33 pre-treated patients, and many responses were durable.…”

Options in metastatic urothelial cancer after first-line therapy

“…Another PD-L1 antibody, pembrolizumab, has also been evaluated in 32 patients with MUC, many were heavily pretreated (33% had >3 prior chemotherapy regimens). ORR was 24% with stable disease demonstrated in another 14% of patients, and OS was 9.3 months [41].…”

Molecular biology and targeted therapies for urothelial carcinoma

“…At six months, 58% of the patients were still alive. With a median OS of 9.3 months, the antitumoral activity of this drug is of interest, particularly as the patient population was heavily pretreated (33% of patients received P3 lines of prior treatment) [104].…”